CLNN

+ Watchlist + Portfolio

Clene Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.19
52-Week Range: $3.88 – $13.50
Market Cap: $56.15M
P/E (TTM): —
EPS (TTM): -3.55
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -56.06%
Gross Margin: 82.84%
Operating Margin: -13740.00%
Profit Margin: 0.00%
Current Ratio: 1.94
Debt/Equity: —
Total Debt: $22.05M
Free Cash Flow: $-11.58M
Revenue Growth: -81.50%
Earnings Growth: —
Enterprise Value: $69.01M

CLNN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$473.00K	$654.00K	$342.00K	$200.00K
Cost of Revenue	$26.00K	$121.00K	$70.00K	$43.00K
Gross Profit	$447.00K	$533.00K	$272.00K	$157.00K
Research & Development	$31.92M	$26.66M	$20.06M	$14.01M
Selling, General & Admin	$16.16M	$12.83M	$12.43M	$8.43M
Operating Expenses	$45.00M	$38.79M	$32.25M	$21.97M
Operating Income	-$44.56M	-$38.26M	-$31.98M	-$21.82M
EBITDA	-$25.60M	-$43.24M	-$33.69M	-$22.00M
Pretax Income	-$29.92M	-$49.50M	-$39.40M	-$26.17M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$29.92M	-$49.50M	-$39.40M	-$26.17M
Diluted EPS	-9.20	-9.43	-5.67	-2.65
Diluted Shares	3.26M	5.25M	6.95M	9.86M

CLNN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.33M	$28.82M	$12.15M	$5.19M
Receivables	$2.97M	$1.34M	$391.00K	$590.00K
Inventory	$43.00K	$37.00K	$68.00K	$37.00K
Current Assets	$29.20M	$38.85M	$16.16M	$8.98M
Total Assets	$44.49M	$52.34M	$27.34M	$18.13M
Current Liabilities	$13.86M	$25.33M	$10.29M	$10.78M
Long-Term Debt	$19.25M	$7.15M	$15.43M	$13.54M
Total Debt	$31.82M	$32.16M	$20.84M	$21.67M
Total Liabilities	$41.26M	$38.95M	$36.19M	$35.72M
Retained Earnings	-$193.22M	-$242.72M	-$282.12M	-$308.30M
Shareholders' Equity	$3.24M	$13.39M	-$8.86M	-$17.59M
Working Capital	$15.34M	$13.52M	$5.87M	-$1.80M
Net Debt	$7.34M	—	$3.63M	$12.43M

CLNN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$39.01M	-$30.17M	-$21.33M	-$18.55M
Capital Expenditure	-$5.18M	-$330.00K	-$15.00K	-$39.00K
Free Cash Flow	-$44.19M	-$30.50M	-$21.34M	-$18.59M
Depreciation & Amortisation	$1.02M	$1.71M	$1.65M	$1.50M
Stock-Based Compensation	$8.51M	$9.12M	$7.95M	$6.38M
Investing Cash Flow	-$10.16M	-$1.50M	$6.32M	-$39.00K
Financing Cash Flow	$17.25M	$42.16M	-$1.53M	$11.52M
Net Change in Cash	-$31.93M	$10.49M	-$16.54M	-$7.07M

CLNN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$81.00K	$27.00K	$15.00K	$77.00K	$15.00K
Cost of Revenue	$20.00K	$0.00	$0.00	$23.00K	$0.00
Gross Profit	$61.00K	$27.00K	$15.00K	$54.00K	$15.00K
Research & Development	$1.48M	$3.51M	$3.51M	$5.50M	$329.00K
Selling, General & Admin	$2.44M	$2.19M	$1.98M	$1.81M	$1.63M
Operating Expenses	$3.63M	$5.66M	$5.39M	$7.30M	$1.71M
Operating Income	-$3.57M	-$5.63M	-$5.37M	-$7.24M	-$1.69M
EBITDA	$261.00K	-$6.37M	-$7.76M	-$8.12M	-$6.95M
Pretax Income	-$751.00K	-$7.42M	-$8.78M	-$9.23M	-$8.09M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$751.00K	-$7.42M	-$8.78M	-$9.23M	-$8.09M
Diluted EPS	-0.09	-0.78	-0.85	—	-0.69
Diluted Shares	8.82M	9.52M	10.28M	—	11.64M

CLNN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$9.83M	$7.29M	$7.92M	$5.19M	$5.94M
Receivables	$1.51M	$1.32M	$550.00K	$590.00K	$3.51M
Inventory	$38.00K	$79.00K	$61.00K	$37.00K	$54.00K
Current Assets	$14.67M	$11.98M	$12.67M	$8.98M	$13.02M
Total Assets	$25.31M	$22.13M	$22.31M	$18.13M	$21.66M
Current Liabilities	$10.76M	$7.57M	$8.31M	$10.78M	$6.73M
Long-Term Debt	$12.91M	$15.75M	$15.79M	$13.54M	$16.34M
Total Debt	$20.94M	$20.85M	$21.31M	$21.67M	$22.05M
Total Liabilities	$30.29M	$30.68M	$34.67M	$35.72M	$40.47M
Retained Earnings	-$282.87M	-$290.29M	-$299.07M	-$308.30M	-$316.39M
Shareholders' Equity	-$4.97M	-$8.55M	-$12.36M	-$17.59M	-$18.81M
Working Capital	$3.91M	$4.41M	$4.37M	-$1.80M	$6.29M
Net Debt	$6.20M	$8.84M	$9.12M	$12.43M	$12.27M

CLNN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.01M	-$4.74M	-$3.99M	-$4.80M	-$4.53M
Capital Expenditure	—	—	—	-$28.00K	—
Free Cash Flow	-$5.01M	-$4.74M	-$4.00M	-$4.83M	-$4.53M
Depreciation & Amortisation	$404.00K	$366.00K	$365.00K	$360.00K	$355.00K
Stock-Based Compensation	$1.95M	$1.37M	$1.70M	$1.36M	$1.31M
Investing Cash Flow	$0.00	$0.00	-$11.00K	-$28.00K	$0.00
Financing Cash Flow	$2.67M	$2.13M	$4.64M	$2.07M	$5.23M
Net Change in Cash	-$2.34M	-$2.61M	$639.00K	-$2.76M	$706.00K

Market Snapshot

About

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotechnology-based therapeutics for neurodegenerative diseases. Based in Salt Lake City, Utah, the company's lead asset is CNM-Au8, a suspension of gold nanocrystals designed to improve cellular energetics and neuroprotection. Clene is advancing CNM-Au8 in clinical trials for amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease, targeting mitochondrial dysfunction underlying these conditions. The company's nanomedicine platform aims to deliver therapeutic benefits through catalytic mechanisms rather than traditional pharmacology.